Vascular Biogenics Ltd. (VBLT)

Amalgamated Bank lessened its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) by 4.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 8,561 shares of the medical instruments supplier’s stock after selling 379 shares during the quarter. Amalgamated Bank’s holdings in LeMaitre Vascular were worth $486,000 at the end of the most recent reporting period. A number of other large investors have also modified their holdings of LMAT. Conestoga Capital Advisors LLC raised its position in shares of LeMaitre Vascular by 0.5% in the 4th quarter. Conestoga Capital Advisors LLC now owns 1,927,971 shares of the medical instruments supplier’s stock valued at $109,432,000 after purchasing an additional 10,390 shares during the last quarter. Vanguard Group Inc. raised its holdings in LeMaitre Vascular by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,510,567 shares of the medical instruments supplier’s stock worth $82,296,000 after purchasing an additional 33,500 shares during the period. Copeland Capital Management LLC boosted its position in LeMaitre Vascular by 2.3% during the fourth quarter. Copeland Capital Management LLC now owns 1,259,961 shares of the medical instruments supplier’s stock worth $71,515,000 after purchasing an additional 28,720 shares in the last quarter. Ranger Investment Management L.P. grew its holdings in LeMaitre Vascular by 15.8% in the third quarter. Ranger Investment Management L.P. now owns 898,822 shares of the medical instruments supplier’s stock valued at $48,968,000 after purchasing an additional 122,601 shares during the period. Finally, Russell Investments Group Ltd. increased its position in shares of LeMaitre Vascular by 6.7% in the fourth quarter. Russell Investments Group Ltd. now owns 288,212 shares of the medical instruments supplier’s stock valued at $16,359,000 after buying an additional 18,223 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock. Analyst Ratings Changes LMAT has been the topic of a number of recent analyst reports. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, May 11th. KeyCorp initiated coverage on shares of LeMaitre Vascular in a research note on Tuesday, February 6th. They set a “sector weight” rating for the company. Barrington Research raised their price target on shares of LeMaitre Vascular from $69.00 to $79.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. Stifel Nicolaus upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $59.00 to $75.00 in a research note on Friday, April 26th. Finally, JMP Securities raised their target price on LeMaitre Vascular from $72.00 to $77.00 and gave the company a “market outperform” rating in a research report on Friday, May 3rd. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $73.83. View Our Latest Research Report on LMAT LeMaitre Vascular Stock Performance NASDAQ:LMAT opened at $78.45 on Monday. LeMaitre Vascular, Inc. has a one year low of $44.27 and a one year high of $79.19. The stock has a market cap of $1.76 billion, a PE ratio of 51.95, a P/E/G ratio of 2.39 and a beta of 0.88. The stock has a 50 day moving average price of $67.83 and a 200 day moving average price of $60.79. LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last issued its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.05. The business had revenue of $53.48 million during the quarter, compared to the consensus estimate of $51.50 million. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. The company’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same period last year, the company earned $0.27 EPS. As a group, analysts predict that LeMaitre Vascular, Inc. will post 1.78 earnings per share for the current fiscal year. LeMaitre Vascular Announces Dividend The company also recently declared a quarterly dividend, which will be paid on Thursday, May 30th. Stockholders of record on Thursday, May 16th will be paid a $0.16 dividend. The ex-dividend date of this dividend is Wednesday, May 15th. This represents a $0.64 annualized dividend and a dividend yield of 0.82%. LeMaitre Vascular’s dividend payout ratio (DPR) is 42.38%. Insider Transactions at LeMaitre Vascular In related news, Director David B. Roberts sold 5,025 shares of the company’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $75.62, for a total value of $379,990.50. Following the transaction, the director now directly owns 14,114 shares in the company, valued at $1,067,300.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director David B. Roberts sold 5,025 shares of the business’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $75.62, for a total value of $379,990.50. Following the sale, the director now directly owns 14,114 shares in the company, valued at approximately $1,067,300.68. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Lawrence J. Jasinski sold 5,110 shares of the stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total transaction of $344,925.00. Following the transaction, the director now directly owns 5,309 shares of the company’s stock, valued at approximately $358,357.50. The disclosure for this sale can be found here. Insiders sold 195,967 shares of company stock worth $14,072,324 in the last 90 days. Insiders own 10.79% of the company’s stock. LeMaitre Vascular Company Profile (Free Report) LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. Read More Five stocks we like better than LeMaitre Vascular Profitably Trade Stocks at 52-Week Highs MarketBeat Week in Review – 5/13 – 5/17 How to Invest in Tech Stocks and Top Tech Stocks to Consider Take-Two Interactive Software Offers 2nd Chance for Investors How to Know Which Cryptocurrency to Buy: A Guide for Investors Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook

- Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol “NTBL” effective at market open on October 17 -

Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved Israeli Corporate Actions MODI'IN, Israel and NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced that its shareholders voted to approve the previously announced proposed merger (the “Merger”) with Notable Labs, Inc. (“Notable”), at the annual and special meeting (the “Meeting”) which took place today, October 12, 2023. Over 98% of the votes cast at the Meeting were cast in favor of the approval of the Merger.

Shareholders of record as of September 5, 2023 are eligible to vote at the VBL Shareholder Meeting on October 12, 2023 Shareholders of record as of September 5, 2023 are eligible to vote at the VBL Shareholder Meeting on October 12, 2023

Merger with Notable expected to close in mid-October, subject to shareholder approval Special shareholder meeting scheduled for October 12, 2023 MODI'IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced that its registration statement on Form S-4 in connection with the proposed merger with Notable Labs, Inc. (“Notable”) has been declared effective by the U.S. Securities and Exchange Commission (“SEC”).

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Vascular Biogenics Ltd. operating as VBL Therapeutics, (the “Company”) (NasdaqGM: VBLT) with Notable Labs, Inc. Under the terms of the proposed transaction, Vascular shareholders will end up owning approximately 24% of the combined company, each on a fully-diluted basis and subject to adjustment. KSF is seek.

Merger with Notable expected to close in late September or October, subject to VBL's S-4 registration statement being declared effective and shareholder approval

Stocks that are priced below $5 per share are typically referred to as penny stocks. However, for the purpose of this article, we will be focusing specifically on penny stocks that are priced under $1.

Penny stocks under $1 to watch this week. The post Penny Stocks To Buy?

Penny stocks to watch trading for pennies this week. The post Penny Stocks To Buy?

Penny stocks under $1 The post 10 Penny Stocks Under $1 To Watch Now, Time To Buy? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

$1 Penny stocks to watch this week. The post 7 Penny Stocks Under $1 To Watch Now, Time To Buy?

Penny stocks to watch this week. The post Penny Stocks To Buy: 5 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Efficient capital deployment in Israel and Singapore designed to support scale-up in key markets REHOVOT, Israel–(BUSINESS WIRE)–#COP26—Aleph Farms, the first company to grow cultivated steaks directly from non-modified cow cells, today announced that it has acquired a manufacturing facility in Modi’in, Israel, and certain related assets from biotechnology company VBL Therapeutics (Nasdaq: VBLT). In addition, […]...

$1 Penny Stocks To Watch The post 4 Penny Stocks Under $1 To Watch Now, Time To Buy? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Vascular Biogenics Ltd. operating as VBL Therapeutics, (the “Company”) (NasdaqGM: VBLT) with Notable Labs, Inc. Under the terms of the proposed transaction, Vascular shareholders will end up owning approximately 24% of the combined company, each on a fully-diluted basis and subject to adjustment. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgm-vblt/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.